$TGTX
TG THERAPEUTICS, INC. Stock $tgtx

$tgtx Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000143774924033948 Filed on November 07, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$83.88M	$165.8M
YoY Change		-49.41%	176298.94%
Cost Of Revenue		$9.341M	$3.509M
YoY Change		166.2%	175350.0%
Gross Profit		$74.54M	$162.3M
YoY Change		-54.08%	176319.57%
Gross Profit Margin		88.86%	97.88%
Selling, General & Admin		$41.97M	$32.77M
YoY Change		28.07%	129.89%
% of Gross Profit		56.3%	20.19%
Research & Development		$20.14M	$14.75M
YoY Change		36.5%	-29.08%
% of Gross Profit		27.02%	9.09%
Depreciation & Amortization		$11.00K	$70.00K
YoY Change		-84.29%	-7.89%
% of Gross Profit		0.01%	0.04%
Operating Expenses		$62.10M	$47.52M
YoY Change		30.68%	35.56%
Operating Profit		$12.43M	$114.8M
YoY Change		-89.17%	-428.3%
Interest Expense		-$10.83M	$3.713M
YoY Change		-391.73%	125.3%
% of Operating Profit		-87.12%	3.23%
Other Income/Expense, Net		$2.666M	-$854.0K
YoY Change		-412.18%	-0.12%
Pretax Income		$4.268M	$113.9M
YoY Change		-96.25%	-418.0%
Income Tax		$388.0K	$0.00
% Of Pretax Income		9.09%	0.0%
Net Earnings		$3.880M	$113.9M
YoY Change		-96.59%	-418.08%
Net Earnings / Revenue		4.63%	68.71%
Basic Earnings Per Share		$0.03	$0.80
Diluted Earnings Per Share		$0.02	$0.73
COMMON SHARES
Basic Shares Outstanding	155.7M	154.8M	151.0M
Diluted Shares Outstanding		160.7M	155.9M

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$341.0M	$229.2M
YoY Change	48.8%	30.27%
Cash & Equivalents	$195.8M	$150.9M
Short-Term Investments	$145.2M	$78.30M
Other Short-Term Assets	$32.63M	$12.08M
YoY Change	170.11%	308.97%
Inventory	$84.67M	$33.55M
Prepaid Expenses
Receivables	$115.7M	$39.30M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$574.1M	$319.1M
YoY Change	79.89%	74.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.411M	$133.0K
YoY Change	5472.18%	-64.63%
Goodwill		$799.0K
YoY Change		0.0%
Intangibles
YoY Change
Long-Term Investments	$1.125M	$0.00
YoY Change		-100.0%
Other Assets	$2.114M	$1.300M
YoY Change	62.62%	2.44%
Total Long-Term Assets	$11.95M	$11.95M
YoY Change	-0.07%	-65.82%
TOTAL ASSETS
Total Short-Term Assets	$574.1M	$319.1M
Total Long-Term Assets	$11.95M	$11.95M
Total Assets	$586.0M	$331.1M
YoY Change	77.01%	51.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$101.4M	$39.70M
YoY Change	155.43%	33.55%
Accrued Expenses	$11.32M	$9.800M
YoY Change	15.47%	65.71%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00
YoY Change
Total Short-Term Liabilities	$125.1M	$57.68M
YoY Change	116.92%	58.25%
LONG-TERM LIABILITIES
Long-Term Debt	$244.2M	$98.91M
YoY Change	146.85%	41.22%
Other Long-Term Liabilities	$24.59M	$9.700M
YoY Change	153.45%	-11.21%
Total Long-Term Liabilities	$244.2M	$98.91M
YoY Change	146.85%	41.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$125.1M	$57.68M
Total Long-Term Liabilities	$244.2M	$98.91M
Total Liabilities	$393.9M	$166.3M
YoY Change	136.84%	41.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.600B	-$1.500B
YoY Change	6.67%	0.0%
Common Stock	$156.0K	$151.0K
YoY Change	3.31%	4.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.400M
YoY Change
Treasury Stock Shares
Shareholders Equity	$192.2M	$164.8M
YoY Change
Total Liabilities & Shareholders Equity	$586.0M	$331.1M
YoY Change	77.01%	51.94%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	$3.880M	$113.9M
YoY Change	-96.59%	-418.08%
Depreciation, Depletion And Amortization	$11.00K	$70.00K
YoY Change	-84.29%	-7.89%
Cash From Operating Activities	-$12.21M	$83.71M
YoY Change	-114.58%	-342.67%
INVESTING ACTIVITIES
Capital Expenditures	$24.00K	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$9.310M	-$30.23M
YoY Change	-69.2%	912.39%
Cash From Investing Activities	-$9.334M	-$30.23M
YoY Change	-69.12%	911.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	134.5M	420.0K
YoY Change	31912.86%	52.73%
NET CHANGE
Cash From Operating Activities	-12.21M	83.71M
Cash From Investing Activities	-9.334M	-30.23M
Cash From Financing Activities	134.5M	420.0K
Net Change In Cash	112.9M	53.90M
YoY Change	109.49%	-244.85%
FREE CASH FLOW
Cash From Operating Activities	-$12.21M	$83.71M
Capital Expenditures	$24.00K	$0.00
Free Cash Flow	-$12.23M	$83.71M
YoY Change	-114.61%	-342.7%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Registrant Name EntityRegistrantName	TG THERAPEUTICS, INC.
	dei	Entity Central Index Key EntityCentralIndexKey	0001001316
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	190000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	155910901
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	151465598
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	155777291
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	151424289
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	133610
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	41309
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	800000	usd
	tgtx	Lessee Operating Lease Option To Extend Additional Term LesseeOperatingLeaseOptionToExtendAdditionalTerm	P2Y
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-32639
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	36-3898269
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3020 Carrington Mill Blvd, Suite 475
	dei	Entity Address City Or Town EntityAddressCityOrTown	Morrisville
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NC
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	27560
	dei	City Area Code CityAreaCode	877
	dei	Local Phone Number LocalPhoneNumber	575-8489
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
	dei	Trading Symbol TradingSymbol	TGTX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	155665334
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	195822000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92933000	usd
CY2024Q3	us-gaap	Short Term Investments ShortTermInvestments	145219000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	124575000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	115727000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	51093000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	84669000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	39823000	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	32632000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	9519000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	574069000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	317943000	usd
CY2024Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1295000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1285000	usd
CY2024Q3	us-gaap	Long Term Investments LongTermInvestments	1125000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	0	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7411000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8050000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2114000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2309000	usd
CY2024Q3	us-gaap	Assets Assets	586014000	usd
CY2023Q4	us-gaap	Assets Assets	329587000	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	101407000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	38471000	usd
CY2024Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3298000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1479000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1231000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1446000	usd
CY2024Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	9093000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	152000	usd
CY2024Q3	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	10085000	usd
CY2023Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	12172000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	125114000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	53720000	usd
CY2024Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	16166000	usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	6016000	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	244158000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	100118000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8419000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9231000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	393857000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	169085000	usd
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	156000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	151000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1746909000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1713162000	usd
CY2024Q3	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	2383000	usd
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	234000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1552525000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1552577000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	192157000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	160502000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	586014000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	329587000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	83879000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	165815000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	220819000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	189691000	usd
CY2024Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9341000	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3509000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	23087000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6277000	usd
CY2024Q3	tgtx	Non Cash Compensation Research And Development Expenses NonCashCompensationResearchAndDevelopmentExpenses	3028000	usd
CY2023Q3	tgtx	Non Cash Compensation Research And Development Expenses NonCashCompensationResearchAndDevelopmentExpenses	2915000	usd
	tgtx	Non Cash Compensation Research And Development Expenses NonCashCompensationResearchAndDevelopmentExpenses	8000000	usd
	tgtx	Non Cash Compensation Research And Development Expenses NonCashCompensationResearchAndDevelopmentExpenses	10162000	usd
CY2024Q3	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	17110000	usd
CY2023Q3	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	11838000	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	62417000	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	48581000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20138000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14753000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	70417000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	58743000	usd
CY2024Q3	tgtx	Non Cash Compensation Selling General And Administrative Expenses NonCashCompensationSellingGeneralAndAdministrativeExpenses	8745000	usd
CY2023Q3	tgtx	Non Cash Compensation Selling General And Administrative Expenses NonCashCompensationSellingGeneralAndAdministrativeExpenses	6269000	usd
	tgtx	Non Cash Compensation Selling General And Administrative Expenses NonCashCompensationSellingGeneralAndAdministrativeExpenses	22593000	usd
	tgtx	Non Cash Compensation Selling General And Administrative Expenses NonCashCompensationSellingGeneralAndAdministrativeExpenses	18386000	usd
CY2024Q3	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	33221000	usd
CY2023Q3	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	26500000	usd
	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	92742000	usd
	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	73167000	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	41966000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	32769000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	115335000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	91553000	usd
CY2024Q3	us-gaap	Costs And Expenses CostsAndExpenses	71445000	usd
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	51031000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	208839000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	156573000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	12434000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	114784000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	11980000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	33118000	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	10832000	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	3713000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	16967000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	10184000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2666000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2859000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5128000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4154000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8166000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-854000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-11839000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6030000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	4268000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	113930000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	141000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	27088000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	388000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	89000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	3880000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	113930000	usd
	us-gaap	Net Income Loss NetIncomeLoss	52000	usd
	us-gaap	Net Income Loss NetIncomeLoss	27088000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.8
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.19
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.73
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.19
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	145102479
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	142871227
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	145342337
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	141571785
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	160714388
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	155871749
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	160366927
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	145952913
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	58587000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	363000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	595000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	7120000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-39232000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	27433000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	751000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	46297000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	13582000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-47610000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	40453000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	420000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	9966000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	113930000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	164769000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	160502000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	10304000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-10707000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	160109000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	135000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	10445000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	6879000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	177568000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	199000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	usd
CY2024Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	2149000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	12659000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	3880000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	192157000	usd
	us-gaap	Net Income Loss NetIncomeLoss	52000	usd
	us-gaap	Net Income Loss NetIncomeLoss	27088000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4607000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	30593000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	28548000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	59000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	173000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	5287000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	704000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1692000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1739000	usd
	tgtx	Amortization Of Leasehold Interest AmortizationOfLeaseholdInterest	159000	usd
	tgtx	Amortization Of Leasehold Interest AmortizationOfLeaseholdInterest	159000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1402000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1473000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-253000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-0	usd
	tgtx	Change In Fair Value Of Notes Payable ChangeInFairValueOfNotesPayable	-151000	usd
	tgtx	Change In Fair Value Of Notes Payable ChangeInFairValueOfNotesPayable	71000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	42031000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	31432000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	23047000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	10365000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	64634000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	39320000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	60850000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2372000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1790000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1780000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	2851000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	2024000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	19244000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	6637000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14876000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18203000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	237200000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	72551000	usd
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	252625000	usd
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	78447000	usd
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	1375000	usd
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	-0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16824000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5896000	usd
	us-gaap	Proceeds From Repayments Of Secured Debt ProceedsFromRepaymentsOfSecuredDebt	-107553000	usd
	us-gaap	Proceeds From Repayments Of Secured Debt ProceedsFromRepaymentsOfSecuredDebt	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	46297000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	344000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1534000	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	244815000	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	25000000	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	858000	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	125000	usd
	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	2149000	usd
	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	-0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	134599000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	72706000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	102899000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	48607000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	94218000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	103577000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	197117000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	152184000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	195822000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	150902000	usd
CY2024Q3	us-gaap	Restricted Cash RestrictedCash	1295000	usd
CY2023Q3	us-gaap	Restricted Cash RestrictedCash	1282000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	197117000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	152184000	usd
	us-gaap	Interest Paid Net InterestPaidNet	12048000	usd
	us-gaap	Interest Paid Net InterestPaidNet	3929000	usd
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	usd
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	1238000	usd
	tgtx	Warrants Issued With Debt Financing WarrantsIssuedWithDebtFinancing	0	usd
	tgtx	Warrants Issued With Debt Financing WarrantsIssuedWithDebtFinancing	595000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1600000000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	341000000	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Financial Statement Reclassification</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:28pt;">Certain account balances from prior periods have been reclassified in these financial statements to conform to current period classifications.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15611909
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13484492
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	3880000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	113930000	usd
	us-gaap	Net Income Loss NetIncomeLoss	52000	usd
	us-gaap	Net Income Loss NetIncomeLoss	27088000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	145102479
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	142871227
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	145342337
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	141571785
CY2024Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	15611909
CY2023Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	13000522
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	15024590
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	4381128
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	160714388
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	155871749
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	160366927
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	145952913
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.8
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.19
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.73
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.19
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	83879000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	165815000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	220819000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	189691000	usd
CY2024Q3	us-gaap	Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss	145219000	usd
CY2024Q3	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	122000	usd
CY2024Q3	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	3000	usd
CY2024Q3	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	145338000	usd
CY2023Q4	us-gaap	Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss	124575000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	30000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	53000	usd
CY2023Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	124552000	usd
CY2024Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1734000	usd
CY2024Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	74973000	usd
CY2024Q3	us-gaap	Inventory Finished Goods And Work In Process Net Of Reserves InventoryFinishedGoodsAndWorkInProcessNetOfReserves	7962000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	84669000	usd
CY2024Q3	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	872000	usd
CY2024Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	872000	usd
CY2024Q3	tgtx	Forward Contract Liabilities ForwardContractLiabilities	2568000	usd
CY2024Q3	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	508000	usd
CY2024Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	3076000	usd
CY2023Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	357000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	357000	usd
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	190000000
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	92301
CY2024Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	2100000	usd
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	133610
CY2024Q3	us-gaap	Treasury Stock Value TreasuryStockValue	2400000	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11800000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9200000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30600000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	28500000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4697029
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	65063
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	-0
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4631966
CY2024Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	551000	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	535000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1702000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1632000	usd
CY2024Q3	us-gaap	Lease Cost LeaseCost	551000	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	535000	usd
	us-gaap	Lease Cost LeaseCost	1702000	usd
	us-gaap	Lease Cost LeaseCost	1632000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y6M
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1003	pure
	us-gaap	Operating Lease Payments OperatingLeasePayments	1800000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1231000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1446000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8419000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9231000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	9650000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	10677000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	598000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2100000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2080000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1913000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1827000	usd
CY2024Q3	tgtx	Lessee Operating Lease Liability To Be Paid Year Five And Therafter LesseeOperatingLeaseLiabilityToBePaidYearFiveAndTherafter	4715000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	13233000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3583000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	9650000	usd
CY2019Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1025	pure
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	1100000	usd
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	700000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001437749-24-033948-index-headers.html	Edgar Link	pending
0001437749-24-033948-index.html	Edgar Link	pending
0001437749-24-033948.txt	Edgar Link	pending
0001437749-24-033948-xbrl.zip	Edgar Link	pending
ex_716997.htm	Edgar Link	pending
ex_716998.htm	Edgar Link	pending
ex_716999.htm	Edgar Link	pending
ex_717000.htm	Edgar Link	pending
ex_741510.htm	Edgar Link	pending
f01.jpg	Edgar Link	pending
f02.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fujifilm01.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tgtx-20240930.xsd	Edgar Link	pending
tgtx20240930_10q.htm	Edgar Link	pending
tgtx-20240930_cal.xml	Edgar Link	unprocessable
tgtx-20240930_def.xml	Edgar Link	unprocessable
tgtx-20240930_lab.xml	Edgar Link	unprocessable
tgtx-20240930_pre.xml	Edgar Link	unprocessable
tgtx20240930_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TGTX
TG THERAPEUTICS, INC. Stock $tgtx

2024 Q4 Form 10-Q Financial Statement

#000143774924033948 Filed on November 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TGTX TG THERAPEUTICS, INC. Stock $tgtx

2024 Q4 Form 10-Q Financial Statement

#000143774924033948 Filed on November 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TGTX
TG THERAPEUTICS, INC. Stock $tgtx